Document is current
Any future updates will be listed below
-
Authors
Wells, Alvin F.
Jia, Bochao
Xie, Li
Valenzuela, Guillermo J.
Keystone, Edward C.
Li, Zhanguo
Quebe, Amanda K.
Griffing, Kirstin
Otawa, Susan
Haraoui, Boulos
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01721057 at ClinicalTrials.govnct01721044 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-214261
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
https://doi.org/10.1136/annrheumdis-2018-213271
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
https://doi.org/10.1136/annrheumdis-2016-210094
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
https://doi.org/10.1136/rmdopen-2020-001370
Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
https://doi.org/10.1136/rmdopen-2017-000581
THU0114 Effects of smoking on baricitinib efficacy in patients with rheumatoid arthritis: pooled analysis from two phase 3 clinical trials
https://doi.org/10.1136/annrheumdis-2017-eular.1341
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
https://doi.org/10.1136/rmdopen-2018-000662
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
https://doi.org/10.1136/annrheumdis-2017-212461
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
https://doi.org/10.1007/s40744-021-00317-9
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-000898
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2016-000410
Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2017-000546
nct01885078 at ClinicalTrials.govDocuments that mention this clinical trial
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
https://doi.org/10.1136/annrheumdis-2018-213271
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
https://doi.org/10.1136/annrheumdis-2016-209821
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
https://doi.org/10.1136/annrheumdis-2016-210094
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
https://doi.org/10.1136/rmdopen-2020-001370
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
https://doi.org/10.1136/annrheumdis-2017-212461
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
https://doi.org/10.1007/s40744-021-00317-9
FRI0048 NUMBER NEEDED TO TREAT TO ACHIEVE MINIMUM CLINICALLY SIGNIFICANT DIFFERENCES IN PATIENT-REPORTED OUTCOMES IN PATIENTS TREATED WITH BARICITINIB
https://doi.org/10.1136/annrheumdis-2020-eular.1440
SAT0055 Baricitinib showed rapid and greater reduction in pain compared to adalimumab or placebo in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1346
Documents that mention this clinical trial
Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-214261
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
https://doi.org/10.1136/annrheumdis-2018-213271
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
https://doi.org/10.1136/annrheumdis-2016-210094
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-214529
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
https://doi.org/10.1136/rmdopen-2018-000662
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
https://doi.org/10.1136/annrheumdis-2017-212461
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
https://doi.org/10.1007/s40744-021-00317-9
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-000898
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-001095
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 15 February 2021
Accepted: 8 May 2021
First Online: 24 May 2021
